A current page published by an authority, institution, association, university, media outlet or company.
Third-party verification · Reviewed 2026-08-11
Public Evidence & Verifiable Sources
A reviewed register of third-party sources supporting Steven Li's professional identity, industry meetings, association roles, university cooperation, public activities and media coverage.
Evidence architecture
Public Regulatory Evidence Index
Three evidence levels prevent a public claim from being mistaken for project-specific proof.
A document reviewed and retained in the website evidence record but not republished as a public download.
License, audit, validation, capacity or product evidence reviewed only after confidentiality and scope are agreed.
HKEX Application Proof: disclosed caspofungin-acetate technology-transfer arrangement with Hainan Hailing
BrightGene Bio-Medical Technology Co., Ltd. · Hong Kong Exchanges and Clearing Application Proof
BrightGene's 2026 HKEX Application Proof states that it entered into a technology-transfer agreement with Hainan Hailing in 2020, amended in 2022, concerning caspofungin acetate for injection. The draft disclosure states that the arrangement transferred manufacturing-process technology, production approvals and domestic ownership rights, and that Hailing became the marketing authorisation holder in Chinese Mainland. This card reports the issuer's draft disclosure only; it is not independent confirmation of current product status, ongoing API supply, capacity, commercial availability, regulatory status outside Chinese Mainland, or suitability for a new project.
Open HKEX Application Proof →Hainan MPA drug-manufacturer catalogue: Hainan Hailing Chemipharma
Hainan Medical Products Administration · public catalogue
Hainan MPA's public catalogue identifies Hainan Hailing Chemipharma under Drug Manufacturing Licence No. Qiong20160065, with its listed addresses and stated production scope. The entry includes powder injections, lyophilized powder injections, small-volume injections, tablets, hard capsules, creams and ointments, and gives 13 August 2030 as the licence expiry date. This supports the dated catalogue entry only; it does not establish current product authorizations, available capacity, batch release, project suitability, or any certification or inspection outcome.
Open Hainan MPA catalogue page →Browse the current official directory index →Hainan MPA table: listed contract-processing scope for terminally sterilized small-volume injections
Hainan Medical Products Administration · public table
A Hainan MPA table updated 27 July 2026 lists Hainan Hailing as able to undertake contract processing for terminally sterilized small-volume injections, ordinary category, 2 mL and 5 mL specifications, with a maximum annual contract-processing quantity of 5,000 (source unit: 万瓶). This dated public entry supports only the listed scope and table value; it is not a current capacity reservation, product-fit decision, regulatory approval, certification, inspection outcome or service commitment.
Open Hainan MPA public table →National centralized procurement renewal results: Hainan Hailing Chemipharma
Tibet Healthcare Security public-service platform · official attachment
An official selected-results table identifies Hainan Hailing as a selected enterprise in listed dosage-form categories, including entecavir, simvastatin, omeprazole and levofloxacin oral immediate-release dosage forms; and azithromycin, ceftriaxone, ceftazidime, cefminox, voriconazole and cefotaxime injectable dosage forms. This record supports the entries shown in the table only; it does not establish current supply, execution volume, price, market coverage, project suitability, or any quality or regulatory outcome.
Open official selected-results table →Fujian public fulfillment assessment: Hainan Hailing Chemipharma listed with a total score of 100
Fujian Provincial Healthcare Security Administration · official public table
A Fujian provincial public assessment table lists Hainan Hailing Chemipharma as a production enterprise with a total score of 100. This is a time- and region-specific public assessment entry only; it does not establish nationwide fulfillment performance, product quality, capacity, supply, a regulatory outcome, or suitability for any particular project.
Open Fujian public assessment table →Archived copy 2025-04-13Hainan public list: Hainan Hailing Chemipharma / Latamoxef Sodium for Injection
Hainan public industry-service platform · dated public notice
A public notice for the first Hainan provincial manufacturing single-champion enterprise list names Hainan Hailing Chemipharma together with Latamoxef Sodium for Injection. A Hainan Provincial Government portal report states that the provincial Department of Industry and Information Technology announced the first list. These dated records support the province-level public-list association and the named product only; they do not establish a national designation, product availability, pharmaceutical quality certification, current capacity, supply, sales or project suitability.
Open public list entry →Open Hainan government portal report →MIIT 2025 Green Factory List: Hainan Hailing Chemipharma
Ministry of Industry and Information Technology of the PRC
An official MIIT attachment titled 2025 Green Factory List lists Hainan Hailing Chemipharma in the Hainan entries (serial 1699). It supports inclusion in that dated list only; it does not establish pharmaceutical quality certification, GMP/FDA status, product approval, current environmental performance, capacity, supply, sales or project suitability.
Open MIIT attachment →A Hainan industry authority public notice also names Hainan Hailing under its 2025 National Green Factory incentive-plan item. It is a source-access fallback only; it does not establish payment, current environmental performance, pharmaceutical quality, capacity, supply or project suitability.
Open related Hainan authority notice →Hainan regulator field visit to Hailing production and R&D facilities
Hainan Medical Products Administration
A dated Hainan authority news release says its delegation visited Hainan Hailing Pharmaceutical, observed post-holiday resumption and quality-system operations in production workshops and an R&D center. It does not state an inspection classification, approval, certification or a conclusion on compliance for any product or facility.
Open regulator source →Fujian fifth-batch volume-procurement selection list for lyophilized latamoxef sodium injection
Fujian Provincial Healthcare Security Administration
A dated official attachment titled Fujian Province Fifth Batch Centralized Volume Procurement Selected List identifies Hainan Hailing as manufacturer and applicant for lyophilized latamoxef sodium injection entries at 0.25g, 0.5g and 1.0g. This time- and region-bound record does not establish nationwide coverage, current supply, sales volume, price execution or general market position.
Open government source →WIPO public record: lyophilized latamoxef sodium for injection and freeze-drying process
World Intellectual Property Organization (WIPO)
The public WIPO record identifies Hainan Hailing Chemipharma as applicant for an international patent publication concerning a lyophilized latamoxef sodium injection and freeze-drying process. It confirms a published application only—not current patent validity, product availability, technology-transfer readiness or market authorization.
Open WIPO record →Fujian public inquiry listing for latamoxef sodium for injection
Fujian Provincial Healthcare Security Administration
A dated Fujian government public inquiry/listing identifies Hainan Hailing for latamoxef sodium for injection at 1.0g, 0.5g and 0.25g. It is not evidence of tender success, procurement volume, current supply or market performance.
Open government source →Xinhua report: Hainan Hailing added Pakistan and Uganda among export regions in 2025
Xinhua News Agency · dated industry report
A Xinhua report dated 8 January 2026 states that Hainan Hailing Chemipharma added Pakistan and Uganda among its export destinations in 2025. This time-bounded media statement supports only the reported expansion of export regions; it does not identify products, establish product registration, current sales, tender awards, volume, market share, supply continuity or suitability for a particular project.
Open original source →Official list of medicines registered in Madagascar
Madagascar medicines authority
The official register names Hainan Hailing in three sterile injectable entries: amoxicillin/potassium clavulanate, azithromycin and ceftriaxone. The dated record supports a public overseas registration footprint, not current sales or tender claims.
Open original source →Archived copy 2026-02-19Later dated Madagascar medicines register: ceftriaxone entry naming Hainan Hailing
Madagascar medicines authority
An official register dated 8 January 2026 lists ceftriaxone 1 g powder for injection, box of 10 vials (public product code 40800), with Hainan Hailing Chemipharma Corporation Ltd. shown as manufacturer and laboratory. This later, product-specific record supports only the entry shown at that date. It does not establish that the other entries in the September 2025 list remained registered, nor does it establish current sales, tender awards, market share, supply continuity or project suitability.
Open original source →NMPA contract-manufacturing requirements
National Medical Products Administration
The 2025 No. 134 announcement defines responsibilities for quality systems, pre-acceptance evaluation, technical transfer, communication, changes, release, audits and sterile-drug oversight.
Open official source →Hainan Hailing official corporate website
Hainan Hailing Chemipharma Corporation Limited
Use the company website for official corporate and product navigation. This independent personal website does not replace it.
Open official corporate source →U.S. FDA 90-Day Decisional Letter
Dated 8 October 2021 · FEI 3006643956
A reviewed copy records a July 2021 on-site inspection, VAI classification and inspection closure. The letter is not an FDA certification, approval or endorsement and is not republished here as a public download.
Leadership roster of the All-China Pharmaceutical Industry Chamber of Commerce
All-China Federation of Industry and Commerce
The official federation roster lists Li Yiqing among the chamber's leadership and records the positions shown by the source at its latest update.
Open original source →Executive committee list of the Hainan Federation of Industry and Commerce
All-China Federation of Industry and Commerce
The official provincial executive-committee list includes Li Yiqing.
Open original source →Executive committee list of the Jiangsu Federation of Industry and Commerce
All-China Federation of Industry and Commerce
The official provincial executive-committee list includes Li Yiqing.
Open original source →All-China Pharmaceutical Industry Chamber meeting on the 2025 national policy agenda
Yangtze River Pharmaceutical Group
The organizer's report records Li Yiqing's participation as Hailing Pharma president and a chamber vice president.
Open original source →Archived copy 2025-08-14Pharmaceutical industry delegation visit to Hengrui Medicine
All-China Pharmaceutical Industry Chamber / LeadingPharm
The published meeting record identifies Li Yiqing's chamber and Hailing roles and summarizes his remarks on compliance, intelligent manufacturing and value-based marketing.
Open original source →University-industry cooperation visit to Hainan Hailing
Hainan University School of Pharmacy
The university report records Li Yiqing presenting Hailing's development, research priorities and product-development approach.
Open original source →Career interview: from aerospace engineering to pharmaceuticals
Shanghai Securities News / China Securities Network
The long-form interview documents education, aerospace experience, the transition into pharmaceuticals and Hailing management work at the publication date.
Open original source →Archived copy 2022-05-21Hailing Pharma's emergency production and public-health donation activities
People's Daily Online — Hainan
The report records Li Yiqing's participation in coordinating production, quality review and logistics during the public-health response.
Open original source →Archived copy 2026-07-22Public-service platform and enterprise-support report
National Development and Reform Commission
The national government page republishes an interview quotation identifying Li Yiqing as Hainan Hailing's executive president at the publication date.
Open original source →Pharmaceutical manufacturer record for Hainan Hailing Chemipharma
Pharmaceutical Data Center
The database record identifies Hainan Hailing Chemipharma and lists Li Yiqing as enterprise head at the record's publication or update point.
Open original source →Hainan biopharmaceutical R&D voucher public-reward record
National Development and Reform Commission / Hainan Daily
An official national-government page reported that, in the 2021 Hainan biopharmaceutical R&D voucher programme, Hainan Hailing Chemipharma received CNY 9.5 million in R&D reward funding.
Scope boundary: This is a historical public record of a policy reward. It does not establish current R&D capacity, product approvals, certifications, manufacturing capacity, project outcomes or future performance.
Open original source →For the official green-factory listing announcement, see the MIIT announcement page. It is an additional official access path and does not expand the scope of the evidence above.
Quality & Regulatory Partnership · Project Evaluation Pathway
Steven Li (李一青)